Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4+ hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8+ counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.
29 June 2026 in Biomedical Signal Processing and Control
Gait impairments in patients with Parkinson’s Disease (PD) and Normal Pressure Hydrocephalus (NPH) are diagnosed with visual clinical assessments. Despite standardized gait tests and clinicians’ expertise, such approaches can be subjective and challenging due to similar symptoms between the two diseases. Wearable sensors and machine learning (ML) can assist clinicians by offering objective and quantitative assessments of gait impairments that can help distinguishing between PD and NPH. This study consists of a cohort of 12 PD and 11 NPH patients that performed standardized gait tests. Gait was measured by wearable sensors embedded in patients’ shoes: a three-axis gyroscope, a three-axis accelerometer and eight pressure sensors in each insole. Sensors and computational pipeline to extract gait cycle features were validated and calibrated on 21 healthy subjects. ML approaches were employed to identify changes in gait cycle features between the PD and NPH patients groups. Twenty-seven ML classifiers were compared, leading to select linear support vector machines, resulting in a classification accuracy of 0.70 ± 0.28 and an area under the ROC curve of 0.74 ± 0.39. Combining wearable sensors with ML algorithms trained on gait cycle features from those sensors showed the potential for objective differentiation of gait patterns between PD and NPH patients.